Results 1 to 10 of about 23,942 (173)

Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis [PDF]

open access: yesNeurology and Therapy
Introduction Fingolimod (Gilenya®), commonly used for relapsing-remitting multiple sclerosis (RRMS), is the first approved oral immunomodulatory agent.
Feliciana Menna   +5 more
doaj   +2 more sources

Fingolimod

open access: yesReactions Weekly, 2012
Hoofnagle JH.
europepmc   +3 more sources

Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study

open access: yesFrontiers in Pharmacology, 2021
This study aimed to investigate the interactions between fingolimod, a sphingosine 1-phosphate receptor (S1PR) agonist, and melanocortin receptors 1 and 5 (MCR1, MCR5).
Carlo Gesualdo   +17 more
doaj   +1 more source

A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis

open access: yesApplied Sciences, 2022
Fingolimod is a sphingosine 1-phosphate-receptor modulator approved for the oral treatment of relapsing–remitting multiple sclerosis (RRMS), a form of MS characterized by a pattern of exacerbation of neurological symptoms followed by recovery.
Claudia Fracasso   +6 more
doaj   +1 more source

Fingolimod increases parvalbumin-positive neurons in adult mice

open access: yesIBRO Neuroscience Reports, 2022
In recent years, it has been shown that central nervous system agents, such as antidepressants and antiepileptic drugs, reopen a critical period in mature animals.
Hiroshi Ueno   +6 more
doaj   +1 more source

Fingolimod [PDF]

open access: yesNeurology Clinical Practice, 2011
Fingolimod is the first oral disease therapy approved for relapsing-remitting multiple sclerosis (MS). Patients can be switched directly from interferon-β or glatiramer acetate to fingolimod without a washout period. Fingolimod's potent efficacy, oral route of administration, and generally good safety and tolerability make it appealing to patients and ...
Megan H, Hyland, Jeffrey A, Cohen
openaire   +2 more sources

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis

open access: yesClinical Case Reports, 2023
Key Clinical Message Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it
Saeed Vaheb   +3 more
doaj   +1 more source

The antiinflammatory and electrophysiological effects of fingolimod on penicillin-induced rats

open access: yesArquivos de Neuro-Psiquiatria, 2022
Background The fact that inflammation triggers epileptic seizures brings to mind the antiepileptic properties of anti-inflammatory drugs. Objective To investigate the electrophysiological and anti-inflammatory effects of fingolimod on an ...
Canan Akünal Türel   +4 more
doaj   +1 more source

Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. [PDF]

open access: yesPLoS ONE, 2015
OBJECTIVE: Effect of fingolimod in multiple sclerosis (MS) is thought to involve the prevention of lymphocyte egress from lymphoid tissues, thereby reducing autoaggressive lymphocyte infiltration into the central nervous system across blood-brain barrier
Hideaki Nishihara   +7 more
doaj   +1 more source

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities

open access: yesFrontiers in Pharmacology, 2022
Preclinical data indicate that fingolimod improves outcome post-ischaemia. This study used a rigorous study design in normal male C57BL/6JOlaHsd mice and in mice with common stroke comorbidities to further evaluate the translational potential of ...
Andrea C. Diaz Diaz   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy